Victoria's latest ADHD reforms have sparked a crucial conversation in the medical community, especially among pharmacists. But here's where it gets controversial: the government's recent announcement introduces an online emergency prescribing pathway, allowing individuals with ADHD to obtain urgent medication without a specialist's visit. This raises questions about patient safety and the role of pharmacists in this new system.
The Background:
Victoria's new initiative, starting in September, enables people with a prior ADHD diagnosis to access urgent repeat medicine through the Victorian Virtual Emergency Department (VVED). This telehealth service aims to tackle the challenges of lengthy waitlists, rising costs, and the risks of abruptly stopping Schedule 8 ADHD medications, which can cause severe symptoms and distress.
The Process:
Pharmacists should note that VVED clinicians will verify patients' current medication and dosage before issuing prescriptions. These prescriptions will be sent directly to the patient's local pharmacy, with the closest operational pharmacy being advised to the patient. The Department of Health emphasizes that this pathway is for emergencies only and does not replace regular ADHD management.
Eligibility and Limitations:
The service is available to adults and children aged 6 and over with an existing ADHD diagnosis who cannot promptly see their usual clinician. It's crucial to understand that the VVED will not initiate ADHD treatment, adjust dosages, or provide ongoing prescriptions. This service is strictly for those already prescribed ADHD medications.
Safety Measures:
Regulatory requirements and clinical guidelines for ADHD medicines will remain intact. The VVED clinicians, including experienced pediatricians and psychiatrists, will prescribe within their scope of practice. The mandatory use of SafeScript for Schedule 8 medicines will continue, ensuring pharmacists and prescribers can monitor dispensing histories and prevent excessive prescriptions.
National Impact:
This reform is part of a broader shift in Australia to move ADHD care away from specialist-only services. Queensland, ACT, New South Wales, Western Australia, and South Australia have implemented or are planning similar changes, aiming to reduce wait times, costs, and increase GP involvement in ADHD care. However, the focus remains on maintaining strict oversight of Schedule 8 stimulants like methylphenidate, dexamfetamine, and lisdexamfetamine.
Pharmacists play a pivotal role in this evolving landscape, ensuring patient safety and medication management. As the healthcare system adapts, staying informed and engaged is essential. What are your thoughts on this new approach to ADHD care? Is it a step towards better accessibility, or does it raise concerns about patient safety and the role of specialists?
